If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to ...

The stock of Eli Lilly (LLY) is down 4% on news that rival Novo Nordisk (NVO) has begun selling its highly anticipated weight ...

Eli Lilly and Company’s LLY stock has risen 28% in the past three months. With exceptional growth from its GLP-1 drugs, ...

Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

However, the stock has been pressured lately. Especially last week, after the release of its quarterly earnings report for Q2 2025, the stock price pulled by over 15% at one point. All told, the ...

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

In this photo illustration, a Eli Lilly logo seen displayed on a smartphone. Eli Lilly’s stock (NYSE: LLY) has recently surged 27% over the past month, reaching a current price of $1,022. This rally ...

The average one-year price target for Eli Lilly and (XTRA:LLY) has been revised to 880,84 € / share. This is an increase of 11.77% from the prior estimate of 788,08 € dated November 9, 2025. The price ...